Revenue segments as reported by the company.

Software products and services

Drug discovery

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Schrodinger 

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Schrodinger reports robust revenue growth and eyes strategic expansion

Schrodinger delivered strong financial performance in 2022, driven by revenue growth in software and drug discovery segments.
The company's innovative pipeline advancements and focus on neuroscience therapeutics position it well for future growth.
While facing challenges in operating expenses and revenue projections, Schrodinger has opportunities for expansion through partnerships and customer growth.
Capitalizing on existing strengths and addressing challenges will be key for Schrodinger to sustain its growth trajectory and competitive edge.

Schrodinger (SDGR) reports robust Q1 performance and growth opportunities

Schrodinger (SDGR) had a strong Q1 2023, with revenue growth driven by software and drug discovery collaborations.
The company's balance sheet strengthened, but challenges exist with smaller biopharma revenue mix and customer acquisition.
Opportunities lie in capitalizing on existing customer loyalty, potential revenue growth, and continued investments in technology.
Overall, Schrodinger is well-positioned to leverage its strengths and address challenges to drive future growth.

Schrodinger meets revenue expectations, focuses on AI-driven drug discovery

Schrodinger's Q2 2023 earnings call highlighted solid revenue performance, ongoing software revenue discussions, and investments in R&D for platform development. The company showcased strengths in innovative drug discovery methods, progress on proprietary programs, and FDA clearances. Challenges include revenue fluctuations and uncertainties in revenue projections, while opportunities lie in expanding software contracts and leveraging AI for efficiency.

Schrodinger reports solid Q3 growth amidst expense challenges and opportunities

Schrodinger's Q3 performance showed revenue growth driven by software and drug discovery segments, despite increased expenses.
The company's focus on operational efficiency and proprietary programs positions it well for future growth and market expansion.
While facing challenges in managing expenses and uncertainties in partner priorities, Schrodinger remains committed to innovation and value creation.
Opportunities lie in scaling up software usage, evaluating collaboration programs, and leveraging customer interest for revenue growth.

Schrodinger reports strong revenue growth and strategic collaborations in 2023

Schrodinger's financial performance in 2023 reflects growth in total revenue and software revenue, driven by customer expansions and program advancements.
The company's strengths lie in its strategic focus on global biopharma companies, collaborations for AI tools, and the trend towards hosted contracts.
Challenges include forecasting revenue growth, decision-making on program advancement, and factors influencing software revenue dynamics.
Opportunities exist in the increased demand for computational tools, ongoing discussions for software adoption, and the validation of the platform through collaborations.

Schrodinger reports Q1 revenue growth amidst challenges and collaboration opportunities

Schrodinger's Q1 2024 performance reflects revenue growth driven by software revenue, though challenges in China and decreased gross margin were noted.
The company's strengths lie in regained rights to key inhibitors, promising pipeline advancements, and potential growth in ACV and collaboration opportunities.
While facing challenges in profitability and R&D expenses, Schrodinger is well-positioned to capitalize on opportunities in collaborations, funding, and drug development.
Overall, Schrodinger's strategic focus on innovation, partnerships, and pipeline advancement sets the stage for future growth and market expansion.

Schrodinger reports solid Q2 results, eyes strategic growth opportunities

Schrodinger's Q2 performance reflects steady revenue growth and margin improvement, despite operational challenges.
Strategic partnerships, acquisitions, and innovative solutions position Schrodinger for future expansion and market leadership.
Efforts to control expenses, drive revenue growth, and leverage market opportunities will be crucial for Schrodinger's long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference.

Schrödinger to Present at Jefferies London Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger will report its third quarter 2024 financial results on Tuesday, November 12, 2024, before the financial markets open.

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that leads to deeper and more durable responses compared to inhibitors that target only Wee1 or Myt1. The preclinical data also show that SGR-3515 has a favorable ph.

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on October 12, 2024, the company granted (i) a non-statutory stock option to purchase 5,700 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 15,890 shares of the company's common stock to seven newly hired employees. These grants were ma.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and the company's PRMT5-MTA inhibitor program, will be presented during poster sessions at the 36th EORTC-NCI-AACR Symposium (ENA 2024) taking place October 23-25, 2024 in Barcelona, Spain. The SGR-3515 presentation will include data further characterizing SGR-3515 in preclinical oncology models. Wee1 and Myt1 kinases regulate the cell cycle and D.

Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium

NEW YORK , Sept. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Schrodinger, Inc. (NASDAQ: SDGR) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm

Microsoft

Bill Gates has been named the world's richest man a record 18 times. Although the billionaire has shifted his focus to philanthropic efforts as time has gone on, the Bill & Melinda Gates Foundation Trust still relies on stock investments to finance its worthwhile goals.

2 Bill Gates stocks to turn $100 into $1,000 by 2025

RxSight

Twist Bioscience Corp

According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.

The 3 Best Med Tech Stocks to Buy Now

Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Communications Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies Scott Schoenhaus - KeyBanc Conor McKay - BMO Capital Markets David Leibowitz - Citi Matt Hewitt - Craig-Hallam Capital Chris Shibutani - Goldman Sachs Steven Mah - TD Cowen Operator Thank you for standing by. Welcome to Schrödinger's Conference Call to review our Second Quarter 2024 Financial Results.

Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Schrodinger (SDGR) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Schrodinger (SDGR) Q2 Earnings: A Look at Key Metrics

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.21 per share a year ago.

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the second quarter of 2024.

Schrödinger Reports Strong Second Quarter 2024 Financial Results

IonQ

Dave & Buster's

Small-cap stocks have taken a beating in the last two years. After the meme stock craze of 2021 died down, investors found they could get more predictable thrills from large-cap technology stocks.

3 Small-Cap Stocks to Buy at a 52-Week Low

Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline

Best Buy

Tesla

Inflation is trending downward and approaching the Federal Reserve's 2% target and unemployment is heading higher. The Fed is widely expected to begin cutting interest rates at its September meeting.

3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts

NEW YORK--(BUSINESS WIRE)--Schrödinger will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the financial markets close.

Schrödinger to Announce Second Quarter 2024 Financial Results on July 31

CRISPR Therapeutics

Vertex Pharmaceuticals

Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.

3 Top-Rated Gene Editing Stocks Actually Making Money

Schrödinger is a hybrid biopharma company specializing in physics-based computational chemistry and traditional drug development. The company aims to utilize computational methods to create better drug candidates and improve strategic decision-making in clinical trials. Schrödinger has attracted substantial investment from strategic partnerships and has a diverse pipeline of drug candidates in clinical development.

Schrodinger: Buy The Drug-Discovery Platform And Get The Pipeline Nearly For Free

Highlights from analysis from 24/7 Wall Street Analysts Eric Bleeker and Austin Smith can be found below.

1 Growth Stock That Could Dominate AI's Next Breakthrough

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.

Schrödinger to Present at Jefferies Global Healthcare Conference

Absci Corp

Bristol-Myers

Eli Lilly

Novo Nordisk

Novartis

Pfizer

It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?

7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs

Ginkgo Bioworks Holdings

Recursion Pharmaceuticals

Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech.

What's the Difference Between Biotech Stocks and TechBio Stocks?

Schrödinger, Inc. (NASDAQ:SDGR ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Ramy Farid - President and CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therapeutics Jaren Madden - Senior Vice President, Investor Relations and Corporate Communications Conference Call Participants Michael Yee - Jefferies David Leibowitz - Citi Scott Schoenhaus - KeyBanc Vikram Purohit - Morgan Stanley Conor McKay - BMO Steven Mah - TD Cowen Michael Ryskin - Bank of America Matthew Hewitt - Craig-Hallam Capital Joseph Catanzaro - Piper Sandler Chris Shibutani - Goldman Sachs Operator Welcome to Schrödinger's Conference Call to review First Quarter and 2024 Financial Results. My name is Claudette [ph], and I will be your operator for today's call.

Schrödinger, Inc. (SDGR) Q1 2024 Earnings Call Transcript

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.76 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.38 per share a year ago.

Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the first quarter of 2024.

News for Schrodinger Stock (SDGR)